At the time of writing, TG Therapeutics Inc [TGTX] stock is trading at $24.46, up 0.25%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TGTX shares have gain 10.78% over the last week, with a monthly amount glided 22.42%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
TG Therapeutics Inc [NASDAQ: TGTX] stock has seen the most recent analyst activity on August 02, 2023, when Goldman upgraded its rating to a Neutral and also revised its price target to $12 from $16. On May 20, 2022, BofA Securities initiated with a Underperform rating and assigned a price target of $5 on the stock. B. Riley Securities reiterated its Buy rating and decreased its price target to $35 on February 23, 2022. Goldman downgraded its rating to a Sell and reduced its price target to $26 on November 15, 2021. Goldman started tracking with a Neutral rating for this stock on April 20, 2021, and assigned it a price target of $50. In a note dated April 19, 2021, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $79 to $89.
For the past year, the stock price of TG Therapeutics Inc fluctuated between $6.46 and $25.38. Currently, Wall Street analysts expect the stock to reach $26.4 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $24.46 at the most recent close of the market. An investor can expect a potential return of 7.93% based on the average TGTX price forecast.
Analyzing the TGTX fundamentals
According to TG Therapeutics Inc [NASDAQ:TGTX], the company’s sales were 346.73M for trailing twelve months, which represents an 357.05% jump. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.28%. To continue investigating profitability, this company’s Return on Assets is posted at 0.24, Equity is -0.38 and Total Capital is 0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.23 points at the first support level, and at 23.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.88, and for the 2nd resistance point, it is at 25.29.
Ratios To Look Out For
It is important to note that TG Therapeutics Inc [NASDAQ:TGTX] has a current ratio of 3.58. As well, the Quick Ratio is 2.83, while the Cash Ratio is 0.76. Considering the valuation of this stock, the price to sales ratio is 10.92, the price to book ratio is 21.33 and price to earnings (TTM) ratio is 40.76.
Transactions by insiders
Recent insider trading involved Lonial Sagar, Director, that happened on Jun 20 ’24 when 16348.0 shares were sold. Director, Lonial Sagar completed a deal on Jun 17 ’24 to sell 9585.0 shares. Meanwhile, Director Lonial Sagar sold 5000.0 shares on Mar 13 ’24.
